Continual Improvement of the Pharmaceutical Quality System: A Practical FDA, ICH & PIC/S Framework

A pharmaceutical quality system should do more than demonstrate compliance. It should enable an organization to identify emerging risks, understand process performance, learn from quality events, and continuously improve its operations.

For pharmaceutical manufacturers supplying the United States, continual improvement should be integrated into the site’s Pharmaceutical Quality System (PQS), quality risk management program, CAPA system, management review process, and regulatory intelligence activities.

The ICH Q10 Pharmaceutical Quality System provides a lifecycle-based model for an effective pharmaceutical quality system. FDA has adopted Q10 as guidance describing a model for pharmaceutical quality management, while FDA’s Quality Systems guidance also describes a systems-based approach for meeting the CGMP requirements in 21 CFR Parts 210 and 211.

ICH Q9(R1) further emphasizes that quality risk management is an ongoing process: risk decisions should be reviewed as new knowledge, experience, inspections, audits, changes, investigations, and other information become available.

Therefore, continual improvement should not be treated as a single QA project. It should operate as a closed-loop quality management process:

Quality Data → Trend Analysis → Risk Assessment → Management Review → Action → Effectiveness Verification → Learning → Continual Improvement

What Is Continual Improvement in a Pharmaceutical Quality System?

Continual improvement is the systematic process of using quality information, scientific knowledge, risk assessment, and management oversight to improve the effectiveness and robustness of pharmaceutical processes and quality systems. It can involve improvement of:

• Manufacturing processes
• Process controls
• Laboratory systems
• Quality control testing
• Environmental monitoring
• Utilities
• Cleaning and sanitation
• Equipment reliability
• Validation
• Supplier quality
• Deviation management
• CAPA
• Change control
• Complaint management
• Stability programs
• Data integrity
• Computerized systems
• Training
• Documentation
• Regulatory compliance

The goal is not simply to reduce the number of deviations. A mature pharmaceutical quality system should continuously ask: What does our quality data tell us about process performance, product quality, and emerging risk?

FDA, ICH and PIC/S Expectations for Continual Improvement

FDA and the Pharmaceutical Quality System

FDA’s Q10 Pharmaceutical Quality System guidance describes ICH Q10 as a model for an effective pharmaceutical quality system and explains that it can be implemented across the product lifecycle.

FDA’s Quality Systems Approach to Pharmaceutical CGMP Regulations also describes a comprehensive quality-systems model consistent with the CGMP requirements for human and veterinary drugs under 21 CFR Parts 210 and 211.

FDA’s process-validation framework provides another important connection to continual improvement. Its lifecycle approach includes Stage 3 – Continued Process Verification, where ongoing monitoring assures that a manufacturing process remains in a state of control.

For U.S. manufacturers, this means process data should not simply be collected and archived. Appropriate data should be evaluated to determine whether process performance remains controlled and whether improvement or additional investigation is warranted.

ICH Q10 and Continual Improvement

ICH Q10 establishes a framework for the Pharmaceutical Quality System and connects quality-system elements with product and process knowledge throughout the lifecycle. Important PQS concepts include:

• Process performance and product quality monitoring
• Corrective and preventive action
• Change management
• Management review

These mechanisms allow an organization to convert quality information into improvement. The FDA’s current Q8/Q9/Q10 Questions and Answers, R5, published in May 2026, provides additional clarification on implementation of these ICH quality concepts.

ICH Q9(R1): Quality Risk Management as an Ongoing Process

ICH Q9(R1) is particularly important for continual improvement because it describes quality risk management as an ongoing process.

The guideline states that risk management should continue to be used when events may affect an earlier risk-management decision, including planned events such as:

• Product reviews
• Inspections
• Audits
• Change controls

and unplanned events such as:

• Investigation findings
• Recalls
• Other quality events

The frequency of risk review should be based on the level of risk. This creates a direct connection between trend analysis and risk reassessment. For example:

Increasing deviation trend → reassess risk → determine potential product/process impact → implement controls → monitor effectiveness

PIC/S GMP and Pharmaceutical Quality Systems

PIC/S GMP Guide PE 009-17 Chapter 1 describes the Pharmaceutical Quality System and connects quality management, GMP, and quality risk management. It also states that the PQS can extend across the pharmaceutical development lifecycle and support innovation and continual improvement. PIC/S also describes Quality Risk Management as a systematic process involving:

• Assessment
• Control
• Communication
• Review

of risks to medicinal-product quality.

PIC/S has additionally published PI 054-1, concerning evaluation and demonstration of PQS effectiveness with risk-based change management. PIC/S states that effective PQS and change management can support timely management of risks, quality and manufacturing performance, continual improvement and innovation.

As of 2026, PIC/S is also progressing revisions and updates to GMP and qualification/validation guidance, making regulatory intelligence an important component of a globally aligned PQS.

The Four Pillars of Pharmaceutical Quality System Continual Improvement

A practical framework can be built around four interconnected elements:

1. Trend Analysis: Identify patterns and emerging signals from quality data.

2. Quality Risk Management: Determine the significance and potential impact of identified trends.

3. Management Review: Ensure significant quality risks and opportunities receive leadership attention and resources.

4. Regulatory Intelligence: Monitor changes in regulatory expectations and evaluate their potential impact on the PQS.

These four elements should operate as an integrated system rather than independent activities.

1. Trend Analysis: Turning Quality Data into Actionable Information

Pharmaceutical organizations generate large volumes of quality data. Examples include:

• Deviations
• OOS results
• OOT results
• Complaints
• Product returns
• Stability results
• Environmental monitoring
• Water-system results
• Cleaning-validation data
• Process-validation data
• Batch yields
• Rejected batches
• Supplier performance
• Audit observations
• CAPA
• Change controls
• Equipment failures

The objective of trend analysis is to identify patterns that may not be obvious from individual events.

Example: Imagine the following deviation pattern:

Quarter	Equipment-Related Deviations
Q1	1
Q2	2
Q3	5
Q4	7

The increasing frequency should trigger further evaluation. Questions should include:

• Are the deviations related to the same equipment?
• Is the same component failing?
• Are failures occurring during a particular shift?
• Is preventive maintenance effective?
• Are operators adequately trained?
• Is calibration current?
• Is there an emerging process risk?
• Is product quality affected?

Trend analysis therefore becomes the starting point for risk-based decision-making.

GAMP 5 Compliance Guide: What is It and How Modern Requirements Helps

Important Pharmaceutical Quality Metrics to Trend

Deviation Trends

Consider monitoring:

• Total deviations
• Critical deviations
• Major deviations
• Minor deviations
• Recurring deviations
• Department-wise deviations
• Equipment-related deviations
• Human-error-related deviations
• Average closure time

CAPA Trends

Monitor:

• CAPA overdue rate
• CAPA recurrence
• CAPA effectiveness failures
• CAPA originating source
• Average completion time
• Repeated root causes

Laboratory Trends

Monitor:

• OOS
• OOT
• Invalid analytical results
• Repeat testing
• Laboratory investigations
• Instrument failures
• System suitability failures

Manufacturing Trends

Monitor:

• Batch rejection
• Yield variation
• Process deviations
• Process parameter excursions
• Equipment breakdown
• Rework/reprocessing

Microbiology Trends

Monitor:

• Environmental monitoring excursions
• Personnel monitoring
• Water-system microbiology
• Bioburden
• Endotoxin
• Sterility-related events

Product Quality Trends

Monitor:

• Market complaints
• Product returns
• Defects
• Stability failures
• Product recalls
• Field alerts

Why Simple Counting Is Not Enough

A quality department may report: “Deviation numbers increased from 10 to 15.”

But the number alone does not tell management whether the situation represents a meaningful increase in risk. The organization should consider:

• Severity
• Frequency
• Recurrence
• Product impact
• Process impact
• Root cause
• Detectability
• Department
• Equipment
• Material
• Supplier
• Time period

Risk-based analysis provides greater value than simply presenting a monthly or quarterly count.

Statistical Tools for Pharmaceutical Trend Analysis

Depending on the process and data characteristics, useful tools may include:

• Pareto analysis
• Control charts
• Statistical Process Control (SPC)
• Moving averages
• Process capability analysis
• Rate-based analysis
• Recurrence analysis
• Regression analysis
• Failure-mode analysis

The objective should be meaningful decision support, not statistical complexity for its own sake.

2. Quality Risk Management: Converting Trends into Decisions

Once a trend has been identified, the next question is: What is the quality risk associated with the trend?

ICH Q9(R1) supports a science- and risk-based approach to quality decision-making and identifies established tools such as FMEA, FMECA, Fault Tree Analysis, HACCP, HAZOP, and Preliminary Hazard Analysis. Risk assessment should consider:

• Severity
• Probability
• Detectability, where applicable
• Patient impact
• Product-quality impact
• Compliance impact
• Data-integrity impact

The level of formality and documentation should be appropriate to the risk.

Example: Trend Analysis + Risk Assessment

Suppose a tablet manufacturing facility observes increasing compression-machine deviations.

Step 1: Trend

The number of equipment deviations increases over four quarters.

Step 2: Investigation

The organization identifies recurring failures involving the same machine.

Step 3: Risk Assessment

Potential consequences include:

• Weight variation
• Hardness variation
• Friability issues
• Dissolution impact
• Potential batch-quality concerns

Step 4: Improvement

Possible actions may include:

• Preventive-maintenance review
• Equipment assessment
• Replacement of worn components
• Operator training
• SOP revision
• Process-parameter review
• Additional monitoring
• Requalification, where scientifically justified

Step 5: Effectiveness Verification

The organization continues trending equipment-related deviations to determine whether recurrence has been reduced.

This is a practical example of a closed-loop PQS.

3. Management Review: Turning Quality Data into Leadership Decisions

Management review is critical because continual improvement requires:

• Resources
• Accountability
• Cross-functional coordination
• Prioritization
• Leadership support

A management review should not simply consist of a PowerPoint presentation of quality statistics.

It should answer: What are the most important quality risks and what decisions are required?

Key Inputs for Pharmaceutical Management Review

Depending on the site’s PQS, management review may include:

• Quality objectives
• Quality metrics
• Deviation trends
• CAPA
• Change controls
• Complaints
• Recalls
• APQR/PQR
• Stability trends
• OOS/OOT
• Internal audits
• Regulatory inspections
• Supplier performance
• Validation status
• Environmental monitoring
• Data integrity
• Training
• Resource requirements
• Emerging regulatory requirements

PharmGuidances also provides a practical Quality Management SOP covering management review topics such as deviations, CAPA, change control, complaints, recalls, internal audits, preventive maintenance, and continual-improvement initiatives.

From Management Review to Measurable Action

A strong management-review process should establish:

Issue → Risk → Decision → Action → Owner → Due Date → Effectiveness Verification

For example:

Element	Example
Issue	Recurring equipment deviations
Risk	Potential process variability
Decision	Conduct equipment/process assessment
Action	Revise maintenance and monitoring strategy
Owner	Engineering + Production + QA
Due Date	Risk-based target
Effectiveness	Trend deviations after implementation

This creates traceability between management review and measurable improvement.

4. Regulatory Intelligence: Anticipating Regulatory Change

Regulatory intelligence should be an active part of a pharmaceutical PQS. For a U.S.-focused pharmaceutical organization, the regulatory-intelligence process may monitor:

• FDA guidance
• FDA CGMP updates
• FDA inspection trends
• FDA warning letters
• FDA regulatory communications
• ICH guidelines
• USP developments
• PIC/S publications
• Other applicable health-authority requirements

FDA maintains a centralized database of guidance documents and identifies guidance as representing the Agency’s current thinking; FDA also notes that guidance documents generally do not create legally binding requirements by themselves. Therefore, regulatory intelligence should distinguish between:

Law / Regulation → Guidance → Industry Practice → Scientific/Technical Information

Each may have a different regulatory significance.

Regulatory Intelligence Should Lead to a Gap Assessment

A regulatory update should move through a structured workflow:

This prevents regulatory intelligence from becoming merely an email-distribution exercise.

Example: Regulatory Intelligence for Data Integrity

Suppose a pharmaceutical company identifies new or updated regulatory expectations relating to computerized systems or data governance. The organization can evaluate:

• User access
• Audit trails
• Electronic records
• Electronic signatures
• Data backup
• Data restoration
• System administration
• Periodic review
• Computerized-system validation
• Data review
• Supplier/vendor controls

Potential actions may include:

• SOP revision
• Access-control review
• Audit-trail review
• System-risk assessment
• Training
• Validation activities
• Periodic review enhancement

PharmGuidances also provides a dedicated SOP resource covering data integrity and data reliability, including data lifecycle, access control, audit trails, and data governance.

Continual Improvement and Continued Process Verification

Continual improvement should also connect with process validation. FDA’s process-validation guidance describes three lifecycle stages:

1. Process Design
2. Process Qualification
3. Continued Process Verification

The third stage provides ongoing assurance that the process remains in a state of control during routine manufacturing. This is particularly relevant to trend analysis. Manufacturers can evaluate appropriate process data such as:

• Critical process parameters
• Critical quality attributes
• Yield
• In-process controls
• Finished-product results
• Process capability
• Deviations
• Equipment performance

The resulting knowledge can support decisions about process control, investigation, and improvement.

CAPA as a Continual Improvement Mechanism

CAPA should connect quality events with sustainable corrective action. Potential CAPA sources include:

• Deviations
• OOS/OOT
• Complaints
• Audits
• Regulatory inspections
• Recalls
• Nonconformances
• Trends
• Risk assessments

A practical CAPA lifecycle is: Problem Identification → Investigation → Root Cause → Risk Assessment → Action → Implementation → Effectiveness Verification → Closure

PharmGuidances’ CAPA resources similarly describe CAPA as a mechanism for addressing nonconformities and preventing recurrence, with effectiveness verification as an important part of the lifecycle.

Correction vs. Corrective Action vs. Improvement

These concepts should not be confused.

Correction: Addresses the immediate problem.

Corrective Action: Addresses the cause of an existing problem to prevent recurrence.

Improvement Action: Strengthens a process or control to improve performance or reduce potential risk. For example:

Problem: Repeated documentation errors.

Correction: Correct the affected record according to approved GDP procedures.

Corrective action: Determine and address the underlying cause.

Improvement: Strengthen the documentation workflow, training, review controls, or electronic system where justified.

Measuring CAPA Effectiveness

“Training completed” does not necessarily demonstrate CAPA effectiveness. More meaningful effectiveness measures may include:

• Reduced recurrence
• Reduced deviation rate
• Improved process capability
• Improved compliance
• Reduced complaint frequency
• Successful audit outcome
• Sustained performance over a defined monitoring period

The effectiveness criterion should be established based on the nature and risk of the CAPA.

Pharmaceutical Quality Culture and Continual Improvement

A mature PQS depends on people as well as procedures. Employees should be encouraged to:

• Report quality problems
• Escalate potential risks
• Identify recurring issues
• Share lessons learned
• Challenge ineffective processes
• Participate in investigations
• Suggest scientifically justified improvements

The objective should be to understand why a failure occurred and how to prevent recurrence, while maintaining appropriate accountability.

Common Weaknesses in Pharmaceutical Continual Improvement Programs

1. Treating Each Deviation as an Isolated Event: Repeated deviations may indicate a systemic problem.

2. Trending Without Risk Assessment: A trend does not automatically establish the appropriate response.

3. Closing CAPA Without Demonstrating Effectiveness: Implementation alone does not necessarily demonstrate that the problem has been resolved.

4. Management Review Without Decisions: Quality meetings should result in appropriate decisions and accountability.

5. Regulatory Intelligence Without Gap Assessment: Receiving regulatory updates is not the same as evaluating their impact.

6. Excessive KPIs: Too many metrics can obscure meaningful signals.

7. Focusing Only on Inspection Readiness: A robust PQS should support sustainable process and product-quality performance—not simply preparation for an inspection.

A Practical Pharmaceutical Quality Improvement Dashboard 

A site can establish a dashboard such as:

Quality Area	KPI	Trend	Risk Assessment	Potential Action
Deviations	Recurrence rate	Increasing	Required	CAPA
CAPA	Overdue CAPA	Increasing	Required	Resource review
OOS	OOS frequency	Increasing	Required	Investigation
Complaints	Complaint rate	Increasing	Required	Product-quality review
Supplier	Material rejection	Increasing	Required	Supplier assessment
EM	Microbial excursions	Stable/Changing	Risk-based	Continued monitoring
Training	Procedure-related errors	Increasing	Required	Training effectiveness
Regulatory	New requirements	Emerging	Applicability review	Gap assessment

The dashboard should be designed to support quality decisions, not merely reporting.

How an eQMS Can Support Continual Improvement

An electronic Quality Management System can provide a centralized platform for:

• Deviation management
• CAPA
• Change control
• Risk management
• Document management
• Training
• Audit management
• Supplier quality
• Complaints
• Regulatory intelligence
• Quality metrics

Integration can make relationships between different quality events more visible. For example:

Equipment deviations + maintenance delays + operator errors + process variability

may reveal a systemic issue that is difficult to identify when each dataset is reviewed separately.

Technology, however, should support rather than replace scientific assessment and quality oversight.

10-Step Closed-Loop PQS Improvement Model

A practical model for pharmaceutical organizations is:

Step 1 — Collect

Collect quality and process data.

Step 2 — Verify

Confirm data completeness, accuracy, and reliability.

Step 3 — Trend

Identify meaningful patterns and recurring events.

Step 4 — Assess Risk

Evaluate product, process, patient, and compliance implications.

Step 5 — Investigate

Determine the potential root cause or contributing factors.

Step 6 — Review

Escalate significant trends to management review.

Step 7 — Act

Implement CAPA, change control, process improvement or other appropriate actions.

Step 8 — Verify

Assess whether the action achieved its intended result.

Step 9 — Re-Trend

Continue monitoring the affected process.

Step 10 — Learn

Incorporate lessons learned into the PQS, procedures, training, and risk assessments.

Pharmaceutical Quality System Self-Assessment Checklist

A pharmaceutical organization can periodically ask:

1. Are significant quality trends identified proactively?
2. Are recurring deviations systematically evaluated?
3. Are OOS and OOT trends appropriately assessed?
4. Are quality risks periodically reassessed?
5. Are risk assessments updated when new information becomes available?
6. Is management review based on meaningful quality data?
7. Are management decisions documented and tracked?
8. Are CAPA effectiveness checks scientifically justified?
9. Is regulatory intelligence formally managed?
10. Are regulatory changes subjected to applicability and gap assessments?
11. Are process-performance trends reviewed?
12. Are supplier-quality trends monitored?
13. Are complaint trends evaluated?
14. Are stability trends incorporated into quality review?
15. Are data-integrity trends monitored?
16. Are improvement actions assigned to accountable owners?
17. Are resources provided for significant quality risks?
18. Are lessons learned communicated?
19. Are improvement outcomes objectively measured?
20. Does the PQS demonstrate a continuous feedback loop?

FDA, ICH and PIC/S References

FDA – Q10 Pharmaceutical Quality System
FDA describes Q10 as a model for an effective pharmaceutical quality system.

FDA – Quality Systems Approach to Pharmaceutical CGMP Regulations
Provides a quality-systems approach aligned with the CGMP requirements in 21 CFR Parts 210 and 211.

FDA – Process Validation: General Principles and Practices
Provides a lifecycle approach to process validation, including continued process verification.

FDA – Q8, Q9 and Q10 Questions and Answers, R5
The current FDA-posted Q&A was finalized in May 2026 and provides additional implementation clarification.

ICH References

ICH Q9(R1) – Quality Risk Management
Provides principles for science- and risk-based quality decision-making and ongoing risk review.

ICH Q10 – Pharmaceutical Quality System
Provides the internationally harmonized PQS model.

ICH Quality Guidelines
ICH’s quality guideline portfolio includes Q7, Q8, Q9, Q10, Q12, Q13 and Q14, among others.

PIC/S References

PIC/S GMP Guide PE 009-17 – Part I
Includes Pharmaceutical Quality System and Quality Risk Management principles.

PIC/S PI 054-1 – PQS Effectiveness and Risk-Based Change Management
Provides recommendations concerning PQS effectiveness and risk-based change management.

PIC/S Publications
The official PIC/S publication page provides the current GMP Guide and related industry/inspectorate documents.

Frequently Asked Questions

1. What is continual improvement in a pharmaceutical quality system?

Continual improvement is the systematic use of quality data, risk assessment, management review and scientific knowledge to improve pharmaceutical processes, controls and quality-system effectiveness.

2. What is the role of trend analysis in pharmaceutical quality?

Trend analysis identifies recurring problems, process drift, and emerging quality risks that may not be apparent from individual events.

3. Which ICH guideline covers pharmaceutical quality systems?

ICH Q10 provides the Pharmaceutical Quality System model, while ICH Q9 provides the framework for Quality Risk Management.

4. What is ICH Q9(R1)?

ICH Q9(R1) is the revised Quality Risk Management guideline. It emphasizes science-based and risk-based decision-making and ongoing review of quality risks as knowledge and experience develop.

5. What is management review in pharmaceutical QA?

Management review is a structured evaluation by appropriate organizational leadership of quality-system performance, trends, risks, resources, opportunities, and required actions.

6. Why is regulatory intelligence important in pharma?

Regulatory intelligence helps organizations identify relevant changes in regulatory expectations and evaluate their potential impact through applicability and gap assessments.

7. What quality data should pharmaceutical companies trend?

Common data include deviations, CAPA, OOS/OOT, complaints, stability, environmental monitoring, process performance, supplier performance, audit findings, and change controls.

8. How is CAPA related to continual improvement?

CAPA converts identified quality problems or systemic weaknesses into corrective and preventive actions. Effectiveness verification helps determine whether the actions achieved their intended outcome.

9. What is continued process verification?

Continued Process Verification is the ongoing monitoring and evaluation of manufacturing-process performance during routine production. FDA includes it as Stage 3 of its process-validation lifecycle.

10. Does FDA require companies to follow ICH Q10 exactly?

ICH Q10 is implemented as an FDA guidance describing a model for a pharmaceutical quality system. FDA guidance generally represents the Agency’s current thinking and, unless specifically stated otherwise, does not create legally binding requirements by itself. Applicable statutes and regulations remain controlling.

11. How often should quality trends be reviewed?

The appropriate frequency depends on the nature, criticality, and risk of the process or data. High-risk processes may require more frequent monitoring than lower-risk activities.

12. How can an eQMS support continual improvement?

An eQMS can connect deviations, CAPA, risk assessments, change controls, audits, training, complaints, and quality metrics, improving visibility and traceability across the PQS.

Suggested Anchor Text	Existing PharmGuidances Article	Recommended Placement
Key Quality Systems in the Pharmaceutical Industry	Key Quality Systems in the Pharmaceutical Industry	Introduction / PQS section
SOP on Quality Management	SOP On Quality Management	Management Review section
CAPA in the pharmaceutical industry	SOP on Corrective and Preventive Action (CAPA)	CAPA section
Data Integrity and Data Reliability	SOP ON DATA INTEGRITY AND DATA RELIABILITY	Regulatory Intelligence / Data Integrity
Quality Manual for Pharmaceutical Industry	QUALITY MANUAL	PQS section
Good Documentation Practices in Pharma	GOOD DOCUMENTATION PRACTICES	Data / Documentation section
Incident Investigation in Pharmaceutical Industry	SOP ON HANDLING AND INVESTIGATION OF INCIDENT	Trend / Investigation section

These are existing PharmGuidances pages, so they can be used as internal-link targets rather than creating new URLs.

Image Caption:
Closed-loop Pharmaceutical Quality System model integrating trend analysis, quality risk management, management review, and regulatory intelligence.

About PharmGuidances

PharmGuidances provides practical pharmaceutical industry resources covering GMP, GDP, Quality Assurance, Quality Control, Pharmaceutical Quality Systems, CAPA, Risk Management, Validation, Data Integrity, Regulatory Compliance, and GxP requirements for pharmaceutical professionals worldwide.

This article is intended for educational and professional reference. FDA guidance documents generally describe the Agency’s current thinking and are not, by themselves, legally binding requirements. Pharmaceutical organizations should assess applicable statutes, regulations, approved commitments and current regulatory requirements for their specific products, processes and markets.

Pharmaceutical eQMS Digitalization FDA Compliance